F Nollet

AZ Sint-Jan Brugge-Oostende, Bruges, Flanders, Belgium

Are you F Nollet?

Claim your profile

Publications (25)110.74 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Compelling experimental evidence exists for a potent invasion suppressor role of the cell-cell adhesion molecule E-cadherin. In addition, a tumour suppressor effect has been suggested for E-cadherin. In human cancers, partial or complete loss of E-cadherin expression correlates with malignancy. To investigate the molecular basis for this altered expression we developed a comprehensive PCR/SSCP mutation screen for the human E-cadherin gene. For 49 breast cancer patients the occurrence of tumour-specific mutations in the E-cadherin gene was examined. No relevant DNA changes were encountered in any of 42 infiltrative ductal or medullary breast carcinoma samples. In contrast, four out of seven infiltrative lobular breast carcinomas harboured protein truncation mutations (three nonsense and one frameshift) in the extracellular part of the E-cadherin protein. Each of the four lobular carcinomas with E-cadherin mutations showed tumour-specific loss of heterozygosity of chromosomal region 16q22.1 containing the E-cadherin locus. In compliance with this, no E-cadherin expression was detectable by immunohistochemistry in these four tumours. These findings offer a molecular explanation for the typical scattered tumour cell growth in infiltrative lobular breast cancer.
    The EMBO Journal 01/1996; 14(24):6107-15. · 9.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A pseudogene (CTNNAP1) for the human alpha E-catenin gene was isolated from a human genomic phage library. The pseudogene sequence shows 90% similarity to the alpha E-catenin mRNA at the nucleotide level. Thirty-eight stop codons in all three reading frames and multiple other mutations were found, indicating that the pseudogene does not encode a functional protein. No introns were found in the region corresponding to the open reading frame of the alpha E-catenin cDNA, and two direct repeats flank this same region. Hence, the pseudogene can be classified as a processed pseudogene. Polymerase chain reaction with pseudogene-specific primers on genomic DNA and cDNA from human cell lines and healthy blood donors demonstrated the general occurrence of the pseudogene and the lack of its transcription. By fluorescence in situ hybridization the pseudogene was mapped to human chromosome 5q22 and the alpha E-catenin gene to the formerly disputed locus 5q31. This is the first report of a pseudogene for a member of the cadherin-catenin cell-cell adhesion complex.
    Genomics 04/1995; 26(2):410-3. · 3.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The human beta-catenin gene (CTNNB1) has been localized to 3p22-->p21.3 by fluorescence in situ hybridization. Recent studies have suggested the presence of one or more tumor suppressor genes on the short arm of chromosome 3. This raises the possibility that CTNNB1, for which important features are already known, is involved in tumor progression.
    Cytogenetics and cell genetics 02/1995; 70(1-2):68-70.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The human β-catenin gene (CTNNB1) has been localized to 3p22→p21.3 by fluorescence in situ hybridization. Recent studies have suggested the presence of one or more tumor suppressor genes on the short arm of chromosome 3. This raises the possibility that CTNNB1, for which important features are already known, is involved in tumor progression.Copyright © 1995 S. Karger AG, Basel
    Cytogenetic and Genome Research - CYTOGENET GENOME RES. 01/1995; 70:68-70.
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper summarizes the minimal workout of chronic lymphoproliferative disorders in a routine laboratory of haematology as recommended by a team of experienced laboratory supervisors in Belgium, taking into account the specific organisation of healthcare in Belgium, the innovations in the field of molecular analyses and related reimbursement. The starting point was essentially based upon clinical and/or haematological indications and it is emphasized that conclusions should be drawn in close dialogue with the clinician and experts in cytogenetics and histopathology. Reports made in the laboratory should be based upon an integration of cytomorphological, immunophenotypical and molecular data. These guidelines are not intended to be used as universal 'diagnostic pathways', but should be useful in developing local diagnostic pathways. It is well understood that this consensus, being valid anno 2009, may rapidly change with new technologies being introduced and new targets discovered.
    Acta clinica Belgica 64(6):494-504. · 0.59 Impact Factor

Publication Stats

2k Citations
110.74 Total Impact Points

Institutions

  • 2009
    • AZ Sint-Jan Brugge-Oostende
      Bruges, Flanders, Belgium
  • 1995–2001
    • Ghent University
      • Department of Molecular Biotechnology
      Gand, Flanders, Belgium
  • 1998–2000
    • Vlaams Instituut voor Biotechnologie
      • Molecular Biology
      Gand, Flanders, Belgium